Peptides
CJC-1295 (No DAC)
CJC-1295 (No DAC) is a GHRH analog often paired with Ipamorelin in growth hormone research. Below, we compare vendors currently stocking research-grade CJC-1295 — not just a single sales page.
CJC-1295 (No DAC) is a GHRH analog often paired with Ipamorelin in growth hormone research. Below, we compare vendors currently stocking research-grade CJC-1295 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£39.99 – £79.99 | In-house testing | Buy Here → | |
 Amino Vault |
$83.30 | Third-party COA | Buy Here → | |
 American Peptides |
$110.00 | Third-party COA | Buy Here → |
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered for extended stability in circulation compared to native GHRH. The version most commonly referenced in research without the DAC (drug affinity complex) modifier is closer in half-life to native GHRH and is frequently studied in combination with GH secretagogues like Ipamorelin.
Research-grade CJC-1295 (No DAC) is typically supplied as a lyophilized powder in sealed vials, commonly at 2mg or 5mg strengths, intended for laboratory reconstitution and research use only.
CJC-1295 binds GHRH receptors in the anterior pituitary, stimulating synthesis and release of growth hormone. Research has focused on its modified amino-acid sequence, which confers resistance to enzymatic degradation and produces a more sustained GHRH signal than native GHRH in preclinical models.
CJC-1295 is a frequent subject of research examining GHRH receptor signaling and its downstream effects on pulsatile GH and IGF-1 output, often in comparative studies against other GHRH analogs.
Because GHRH analogs and ghrelin-receptor agonists act on distinct receptors upstream of GH release, CJC-1295 is frequently studied alongside secretagogues such as Ipamorelin to examine potential synergistic effects on GH pulse amplitude.
CJC-1295 is not FDA-approved for human use and has not completed large-scale controlled human trials. Reported concerns in available literature and anecdotal reports include injection-site reactions and, due to its GH-axis activity, theoretical concerns about insulin sensitivity that have not been fully characterized in long-term human data.
Doses used in preclinical and small clinical research studies vary by study design and are not established as a standardized human protocol. No FDA-approved human dosage exists for CJC-1295.
Compound X does not sell CJC-1295 (No DAC) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
CJC-1295 research is indexed on PubMed under search terms such as "CJC-1295 GHRH analog" and "growth hormone releasing hormone modified peptide."
New guides, vendor comparisons and compound breakdowns every week.